Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …

Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …

Purpose Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased
anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our …

Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …

We present the rationale and design for MARQUEE, a phase III, randomized, double-blind,
placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in …

BACKGROUND In this superiority study, pemetrexed was compared with erlotinib in pre‐
treated patients with metastatic non–small cell lung cancer (NSCLC). METHODS Patients …

After failure of first-line chemotherapy for advanced non-small cell lung cancer, many
patients remain candidates to receive further antitumor treatment. To guide clinical …